These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 2563893)

  • 21. Studies on the response of growth hormone (GH) secretion to GH-releasing hormone, thyrotropin-releasing hormone, gonadotropin-releasing hormone, and somatostatin in acromegaly.
    Shibasaki T; Hotta M; Masuda A; Imaki T; Obara N; Hizuka N; Takano K; Wakabayashi I; Demura H; Ling N
    J Clin Endocrinol Metab; 1986 Jul; 63(1):167-73. PubMed ID: 2872226
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Growth hormone response to the hypothalamic somatostatinergic activity in acromegalic patients.
    Yang I; Park S; Woo J; Kim S; Kim J; Kim Y; Choi Y
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2492-6. PubMed ID: 9253323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined pyridostigmine-thyrotrophin-releasing hormone test for the evaluation of hypothalamic somatostatinergic activity in healthy normal men.
    Yang I; Woo J; Kim S; Kim J; Kim Y; Choi Y
    Eur J Endocrinol; 1995 Oct; 133(4):457-62. PubMed ID: 7581970
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential effects of somatostatin (SRIH) and a SRIH analog, SMS 201-995, on the secretion of growth hormone and thyroid-stimulating hormone in man.
    Williams TC; Kelijman M; Crelin WC; Downs TR; Frohman LA
    J Clin Endocrinol Metab; 1988 Jan; 66(1):39-45. PubMed ID: 2891721
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insulin-induced hypoglycemia, L-dopa and arginine stimulate GH secretion through different mechanisms in man.
    Masuda A; Shibasaki T; Hotta M; Yamauchi N; Ling N; Demura H; Shizume K
    Regul Pept; 1990 Oct; 31(1):53-64. PubMed ID: 2270318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of lesions in the periventricular nucleus of the preoptic-anterior hypothalamus on growth hormone and thyrotropin secretion and brain somatostatin.
    Critchlow V; Abe K; Urman S; Vale W
    Brain Res; 1981 Oct; 222(2):267-76. PubMed ID: 6116518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of central cholinergic neurotransmission enhancement by pyridostigmine on the growth hormone secretion elicited by clonidine, arginine, or hypoglycemia in normal and obese subjects.
    Cordido F; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 1990 May; 70(5):1361-70. PubMed ID: 2159483
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of somatostatin on plasma insulin and growth hormone levels in basal conditions and after glucagon in normal and acromegalic subjects.
    Massara F; Porzio G; Camanni F; Molinatti GM
    Acta Diabetol Lat; 1975; 12(3-4):219-31. PubMed ID: 1224905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glycemic profile in patients with acromegaly treated with somatostatin analogue.
    Valea A; Carsote M; Ghervan C; Georgescu C
    J Med Life; 2015; 8 Spec Issue(Spec Issue):82-6. PubMed ID: 26361517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma concentrations of growth hormone during hyperglycemic clamp with or without somatostatin infusion in obese subjects.
    Bonora E; Moghetti P; Zenere M; Querena M; Tosi F; Corgnati A; Muggeo M
    J Clin Endocrinol Metab; 1990 Jun; 70(6):1732-4. PubMed ID: 1971827
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute hyperglycemia and activation of the beta-adrenergic system do not exhibit synergistic inhibitory actions on thyrotropin-releasing hormone (TRH)-induced thyroid stimulating hormone (TSH) secretion.
    Park C; Kim E; Sohn S; Yang I; Koh G; Oh S; Woo J; Kim S; Kim J; Kim Y; Oh K; Park S; Park S
    Endocr J; 2005 Feb; 52(1):69-74. PubMed ID: 15758560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of intracellular glucopenia on pulsatile growth hormone secretion: mediation in part by somatostatin.
    Painson JC; Tannenbaum GS
    Endocrinology; 1985 Sep; 117(3):1132-8. PubMed ID: 2862015
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
    Costa AC; Rossi A; Martinelli CE; Machado HR; Moreira AC
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does SMS 201-995 normalize growth hormone secretion in acromegaly? GH day profiles and GH concentrations after oral glucose loading.
    van Liessum PA; Pieters GF; Smals AG; Swinkels LM; Benraad TJ; Kloppenborg PW
    J Endocrinol Invest; 1989 Sep; 12(8):553-7. PubMed ID: 2592740
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the sensitivity of growth hormone secretion to somatostatin in vivo and in vitro in acromegaly.
    Kelijman M; Williams TC; Downs TR; Frohman LA
    J Clin Endocrinol Metab; 1988 Nov; 67(5):958-63. PubMed ID: 2903171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture.
    Ishibashi M; Yamaji T
    J Clin Invest; 1984 Jan; 73(1):66-78. PubMed ID: 6140273
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
    Giusti M; Gussoni G; Cuttica CM; Giordano G
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A close correlation between the inhibitory effects of insulin-like growth factor-I and SMS 201-995 on growth hormone release by acromegalic pituitary tumours in vitro and in vivo.
    Lamberts SW; van Koetsveld P; Hofland L
    Clin Endocrinol (Oxf); 1989 Oct; 31(4):401-10. PubMed ID: 2627746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs.
    Lamberts SW; Zweens M; Verschoor L; del Pozo E
    J Clin Endocrinol Metab; 1986 Jul; 63(1):16-9. PubMed ID: 2872225
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impaired glucose tolerance coincides with abnormal release of growth hormone following a glucose load as well as in response to TRH in acromegaly.
    Zárate A; García IC; Morán C; Fonseca ME
    Horm Metab Res; 1986 Jun; 18(6):400-1. PubMed ID: 3089892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.